Phase II: Melanoma

Study: N/A

ClinicalTrials.gov Id: N/A

A Phase II clinical trial combining Imprime PGG® and bevacizumab (Avastin®) is planned for melanoma patients.

Status: Not recruiting.

Locations: To be announced